Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789423 | 0.87 | HDAC1 (0.35) | CYP3A4CYP2C9GPR119HDAC1HDAC8 | |
| SCHEMBL789145 | 0.87 | GPR119 (0.42) | CYP3A4CYP2C9GPR119HDAC1HDAC8 | |
| Iodomethane SCHEMBL795775 | 0.86 | GPR119 (0.41) | CYP3A4CYP2C9GPR119HDAC1HDAC8 | |
| SCHEMBL789247 | 0.84 | GPR119 (0.39) | CYP3A4CYP2C9GPR119HDAC1HDAC8 | |
| SCHEMBL789215 | 0.82 | FPR2 (0.41) | CYP3A4CYP2C9GPR119HDAC1HDAC8 | |
| SCHEMBL2597001 | 0.82 | FPR2 (0.41) | CYP3A4CYP2C9GPR119HDAC1HDAC8 | |
| SCHEMBL15105289 | 0.82 | BTK (0.33) | CYP3A4CYP2C9GPR119HDAC1HDAC8 | |
| SCHEMBL795708 | 0.82 | GPR119 (0.42) | CYP3A4CYP2C9GPR119SLC6A9 | |
| SCHEMBL790109 | 0.82 | CYP3A4 (0.36) | CYP3A4CYP2C9GPR119HDAC1HDAC8 | |
| SCHEMBL789168 | 0.82 | CYP3A4 (0.36) | CYP3A4CYP2C9GPR119HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616074-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| CN-103221046-A | Piperidinyl-substituted lactams as gpr119 modulators | ARRAY BIOPHARMA INC | 2013-07-24 | — | — | CN | disclosed |
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-07-18 | — | — | US | disclosed |
| WO-2012037393-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR180 | CYP3A4 2241/4885CYP2C9 975/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.